These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 27583403)

  • 41. Delay in diagnosis of influenza A (H1N1)pdm09 virus infection in critically ill patients and impact on clinical outcome.
    Álvarez-Lerma F; Marín-Corral J; Vila C; Masclans JR; González de Molina FJ; Martín Loeches I; Barbadillo S; Rodríguez A;
    Crit Care; 2016 Oct; 20(1):337. PubMed ID: 27770828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza.
    Ikematsu H; Kawai N
    Expert Rev Anti Infect Ther; 2011 Oct; 9(10):851-7. PubMed ID: 21973296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effectiveness and safety of neuraminidase inhibitors in reducing influenza complications: a meta-analysis of randomized controlled trials.
    Falagas ME; Koletsi PK; Vouloumanou EK; Rafailidis PI; Kapaskelis AM; Rello J
    J Antimicrob Chemother; 2010 Jul; 65(7):1330-46. PubMed ID: 20488984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Wolkewitz M; Schumacher M
    Lancet Respir Med; 2014 Jul; 2(7):e8-9. PubMed ID: 24948434
    [No Abstract]   [Full Text] [Related]  

  • 45. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Leonardi-Bee J; Venkatesan S; Muthuri SG; Nguyen-Van-Tam JS; Myles PR;
    Lancet Respir Med; 2014 Jul; 2(7):e10-2. PubMed ID: 24948433
    [No Abstract]   [Full Text] [Related]  

  • 46. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Jones M; Del Mar C; Hama R
    Lancet Respir Med; 2014 Jul; 2(7):e9-e10. PubMed ID: 24948431
    [No Abstract]   [Full Text] [Related]  

  • 47. Statistical and methodological concerns about the beneficial effect of neuraminidase inhibitors on mortality.
    Antes G; Meerpohl JJ
    Lancet Respir Med; 2014 Jul; 2(7):e10. PubMed ID: 24948429
    [No Abstract]   [Full Text] [Related]  

  • 48. Antiviral treatment and vaccination for influenza A(H1N1)pdm09 virus: lessons learned from the pandemic.
    López-Medrano F; Fariñas MC; Payeras A; Pachón J
    Enferm Infecc Microbiol Clin; 2012 Oct; 30 Suppl 4():49-53. PubMed ID: 23116793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predictive clinicopathological features derived from systematic autopsy examination of patients who died with A/H1N1 influenza infection in the UK 2009-10 pandemic.
    Lucas S
    Health Technol Assess; 2010 Dec; 14(55):83-114. PubMed ID: 21208548
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [In vitro and in vivo effects of a long-acting anti-influenza agent CS-8958 (laninamivir octanoate, Inavir) against pandemic (H1N1) 2009 influenza viruses].
    Kubo S; Kakuta M; Yamashita M
    Jpn J Antibiot; 2010 Oct; 63(5):337-46. PubMed ID: 21268406
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Continued emergence and changing epidemiology of oseltamivir-resistant influenza A(H1N1)2009 virus, United Kingdom, winter 2010/11.
    Lackenby A; Moran Gilad J; Pebody R; Miah S; Calatayud L; Bolotin S; Vipond I; Muir P; Guiver M; McMenamin J; Reynolds A; Moore C; Gunson R; Thompson C; Galiano M; Bermingham A; Ellis J; Zambon M
    Euro Surveill; 2011 Feb; 16(5):. PubMed ID: 21315056
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of corticosteroid and neuraminidase inhibitors on survival in patients with respiratory distress induced by influenza virus.
    Huang SF; Fung CP; Perng DW; Wang FD
    J Microbiol Immunol Infect; 2017 Oct; 50(5):586-594. PubMed ID: 26542650
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Emergence of oseltamivir-resistant pandemic H1N1 virus during prophylaxis.
    Baz M; Abed Y; Papenburg J; Bouhy X; Hamelin ME; Boivin G
    N Engl J Med; 2009 Dec; 361(23):2296-7. PubMed ID: 19907034
    [No Abstract]   [Full Text] [Related]  

  • 54. Y155H amino acid substitution in influenza A(H1N1)pdm09 viruses does not confer a phenotype of reduced susceptibility to neuraminidase inhibitors.
    Perez-Sautu U; Pozo F; Cuesta I; Monzon S; Calderon A; Gonzalez M; Molinero M; Lopez-Miragaya I; Rey S; Cañizares A; Rodriguez G; Gonzalez-Velasco C; Lackenby A; Casas I
    Euro Surveill; 2014 Jul; 19(27):14-20. PubMed ID: 25033052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical effectiveness of oseltamivir for influenza A(H1N1) virus with H274Y neuraminidase mutation.
    Kawai N; Ikematsu H; Iwaki N; Kondou K; Hirotsu N; Kawashima T; Maeda T; Tanaka O; Doniwa K; Kashiwagi S
    J Infect; 2009 Sep; 59(3):207-12. PubMed ID: 19619898
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
    Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
    Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Emergence of a multidrug-resistant pandemic influenza A (H1N1) virus.
    van der Vries E; Stelma FF; Boucher CA
    N Engl J Med; 2010 Sep; 363(14):1381-2. PubMed ID: 20879894
    [No Abstract]   [Full Text] [Related]  

  • 58. [Influenza A, pregnancy and neuraminidase inhibitors].
    Montané E; Lecumberri J; Pedro-Botet ML
    Med Clin (Barc); 2011 May; 136(15):688-93. PubMed ID: 20416906
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Influenza viruses resistant to neuraminidase inhibitors.
    Nitsch-Osuch A; Brydak LB
    Acta Biochim Pol; 2014; 61(3):505-8. PubMed ID: 25195142
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.
    Wang B; Dwyer DE; Blyth CC; Soedjono M; Shi H; Kesson A; Ratnamohan M; McPhie K; Cunningham AL; Saksena NK
    Antiviral Res; 2010 Jul; 87(1):16-21. PubMed ID: 20385168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.